"目录号: HY-13678A
Anti-infection-
Meropenem三水合物是碳青霉烯类广谱抗菌素。
Bacterial
相关产品
G-418 disulfate-Anisomycin-Salinomycin-Avibactam sodium-Vancomycin hydrochloride-Hygromycin B-Bleomycin sulfate-Ciprofloxacin-Minocycline hydrochloride-Ampicillin sodium-Tetracycline hydrochloride-Tebipenem-Kanamycin sulfate-Solithromycin-Tedizolid-
生物活性
Description
Meropenem (trihydrate) is a carbapenem antibiotic, which displaying a broad spectrum of antibacterial activity.Target: AntibacterialMeropenem (trihydrate), a new parenteral carbapenem demonstrated increased activity as compared to imipenem against 336 strains of Neisseria gonorrhoeae, 119 strains of Haemophilus influenzae, and 110 strains of H. Ceftriaxone and ciprofloxacin demonstrated activity superior to that of both carbapenems while the activity of ceftazidime was similar to that of meropenem [1]. Meropenem (trihydrate), like imipenem and various experimental penems, may overcome the resistance problems presented by Class I beta-lactamases [2]. Meropenem (trihydrate) was rapidly penetrated to the pleural effusion and was retained for a more prolonged time in the pleural effusion than in the blood of patients with accumulated pleural effusion, and it suggested the usefulness of Meropenem (trihydrate) in antibacterial therapy for patients with pleurisy causing accumulation of pleural effusion [3].Clinical indications: Appendicitis; Bacterial infection; Bacterial meningitis; Bacterial pneumonia; Bacterial respiratory tract infection; Bacterial skin infection; Bacterial urinary tract infection; Bacteroides fragilis infection; Bacteroides infection; Bacteroides thetaiotaomicron infection; Complicated skin and skin structure infectionFDA Approved Date: July 1996Toxicity: In mice and rats, large intravenous doses of meropenem (2200-4000 mg/kg) have been associated with ataxia, dyspnea, convulsions, and mortalities.
Clinical Trial
NCT01158937
St. Michael's Hospital, Toronto-Sunnybrook Health Sciences Centre-University of Toronto
Cystic Fibrosis Pulmonary Exacerbation
May 2010
NCT01554124
PENTA Foundation-Chiesi Farmaceutici S.p.A.
Meningitis
February 2013
Phase 1-Phase 2
NCT01429259
Joseph Kuti-Thrasher Research Fund-Hartford Hospital
Cystic Fibrosis-Pneumonia-Pseudomonas Aeruginosa Infection
February 2012
Phase 4
NCT00621192
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)-The EMMES Corporation
Necrotizing Enterocolitis-Intra-abdominal Infection
June 2008
Phase 1-Phase 2
NCT02506686
Huashan Hospital
Central Nervous System Infections
September 2008
Phase 4
NCT01944319
Qingtao Zhou-Peking University Third Hospital
Lower Respiratory Tract Infection
July 2013
Phase 4
NCT02615041
Sutep Jaruratanasirikul-Prince of Songkla University
Ventilator-Associated Pneumonia
January 2004
Phase 4
NCT02437045
The University of Queensland
Bloodstream Infections
April 2015
Phase 4
NCT00891423
Austin Health
Sepsis
April 2009
NCT02213796
Sutep Jaruratanasirikul-Prince of Songkla University
Initial Phase of Severe Sepsis and Septic Shock
January 2013
Phase 4
NCT01551394
PENTA Foundation-Chiesi Farmaceutici S.p.A.
Sepsis
September 2012
Phase 3
NCT01732250
Mical Paul-European Commission-Rabin Medical Center
Gram-Negative Bacterial Infections
March 2013
Phase 4
NCT00534287
Kompetenznetz Sepsis-AstraZeneca-Bayer
Severe Sepsis-Septic Shock
October 2007
Phase 3
NCT02176122
The University of Queensland-International Society of Chemotherapy-Australian Society for Antimicrobials-Queensland Clinical Trials & Biostatistics Centre-Australasian Society for Infectious Diseases
Bloodstream Infections
February 2014
Phase 4
NCT01292031
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-European Commission
Ventilator-associated Bacterial Pneumonia
May 2012
Phase 3
NCT03174795
Hoffmann-La Roche
Urinary Tract Infections
July 11, 2017
Phase 1
NCT00579956
University of Oxford-Mahidol University-Wellcome Trust
Melioidosis
December 2007
NCT00318994
AstraZeneca
Pancreatitis
February 2002
Phase 4
NCT00462878
PETHEMA Foundation
Allogenic Blood Stem Cell Transplantation-Febrile Neutropenia
November 2002
NCT01455246
University of Padova
Cirrhosis-Ascites-Nosocomial Spontaneous Bacterial Peritonitis
October 2010
Phase 2-Phase 3
NCT02784704
Tetraphase Pharmaceuticals, Inc.
Complicated Intra-abdominal Infections-Complicated Appendicitis
October 13, 2016
Phase 3
NCT01445678
Cubist Pharmaceuticals LLC
Complicated Intra-abdominal Infection
December 1, 2011
Phase 3
NCT01808092
AstraZeneca
Nosocomial Pneumonia (NP)-Ventilator-associated Pneumonia (VAP)
April 2013
Phase 3
NCT00318552
AstraZeneca
Sepsis
January 2002
Phase 4
NCT02503761
Mansoura University
Late Onset Neonatal Sepsis
August 2013
Phase 3
NCT02070757
Cubist Pharmaceuticals LLC
Nosocomial Pneumonia
September 23, 2014
Phase 3
NCT01110382
Janssen Research & Development, LLC
Abscess, Intra-Abdominal-Abdominal Abscess-Abdomen, Acute-Abdominal Pain-Appendicitis-Rupture-Infection-Intestinal Perforation-Peritonitis-Ileus
December 2010
Phase 3
NCT01297842
Mahidol University
Drug Safety
May 2011
Phase 4
NCT01147640
Cubist Pharmaceuticals LLC
Complicated Intra-abdominal Infection
June 2010
Phase 2
NCT02820987
Centre Hospitalier Universitaire de Besancon
Septic Shock
September 2016
Phase 3
NCT01499290
AstraZeneca-Forest Laboratories
Complicated Intra-Abdominal Infection
March 2012
Phase 3
NCT03006679
The Medicines Company
Hospital-Acquired Bacterial Pneumonia-Ventilator-Associated Bacterial Pneumonia-Hospital-Acquired Pneumonia-Ventilator-Associated Pneumonia
February 2017
Phase 3
NCT01726023
AstraZeneca
Complicated Intra-abdominal Infection
January 2013
Phase 3
NCT00752219
Novexel Inc
Complicated Intra-Abdominal Infections
March 2009
Phase 2
NCT02142751
Fundación Pública Andaluza para la gestión de la Investigación en Sevilla-Spanish Network for Research in Infectious Diseases
Infection Due to ESBL Escherichia Coli
July 2014
Phase 3
NCT02972255
Hoffmann-La Roche
Healthy Volunteers
October 31, 2016
Phase 1
NCT02349841
Task Foundation NPC-University Eduardo Mondlane-GlaxoSmithKline-Barcelona Centre for International Health Research-Research Center Borstel
Pulmonary Tuberculosis
September 2014
Phase 2
NCT03174184
Johns Hopkins University
Tuberculosis, Pulmonary
September 1, 2017
Phase 2
NCT03182504
Hoffmann-La Roche
Gram-negative Bacterial Infections
June 15, 2017
Phase 1
NCT03217136
Merck Sharp & Dohme Corp.
Complicated Intra-Abdominal Infection
September 1, 2017
Phase 2
NCT02486627
Achaogen, Inc.
Complicated Urinary Tract Infection-Acute Pyelonephritis
January 2016
Phase 3
NCT00619710
AstraZeneca
Skin Infection-Abscess-Cellulitis
February 2001
Phase 3
NCT03032380
Shionogi-Shionogi Inc.
Healthcare-associated Pneumonia (HCAP)-Hospital Acquired Pneumonia (HAP)-Ventilator Associated Pneumonia (VAP)
July 30, 2017
Phase 3
NCT00771316
Merck Sharp & Dohme Corp.
Urinary Tract Infections
December 2008
Phase 3
NCT00061438
AstraZeneca
Pancreatitis, Acute Necrotizing
February 2003
Phase 4
NCT01597973
University of Michigan
Pneumonia-Blood Stream Infection
October 2012
Phase 3
NCT02475733
AstraZeneca-PRA Health Sciences
Complicated Intra-abdominal Infections
July 31, 2015